Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Buckle, Clive Henry ^a   de Leenheer, Evy ^a   Lawson, Michelle Anne ^a   Yong, Kwee ^b   Rabin, Neil ^b   Perry, Mark ^c   Vanderkerken, Karen ^d   Croucher, Peter Ian ^a,e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE STRUCTURE; CELL COUNT; CELL FUNCTION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR PATHOLOGY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; TRABECULAR BONE;

ANIMALS; BONE AND BONES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; GREEN FLUORESCENT PROTEINS; HUMANS; LUMBAR VERTEBRAE; MICE; MICE, INBRED C57BL; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND;

MURINAE; MUS;

EID: 84865603486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041127     Document Type: Article

References (40)

1. McCloskey EV (2004) Bone Disease. In Gharton G, Durie Brian GM, Samson D (Eds). Multiple Myeloma and Related Disorders. London: Arnold.
2. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV, (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20: 487-493.
3. Melton LJ 3rd, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, et al. (2004) Fracture risk in monoclonal gammopathy of undetermined significance. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 19: 25-30.
4. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
5. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
6. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190-25194.
7. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
8. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S, (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533.
9. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, et al. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98: 11581-11586.
10. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, et al. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540.
11. Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, et al. (2002) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99: 4646-4647; author reply 4647.
12. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, et al. (2003) Expression of Receptor Activator of Nuclear Factor kappaB Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma. Clin Cancer Res 9: 1436-1440.
13. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, et al. (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445.
14. Shipman CM, Holen I, Lippitt JM, E V, Croucher PI, (2000) Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 96: 1552 (Abstr).
15. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, et al. (2002) Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621.
16. Shipman CM, Croucher PI, (2003) Osteoprotegerin Is a Soluble Decoy Receptor for Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo2 Ligand and Can Function as a Paracrine Survival Factor for Human Myeloma Cells. Cancer Res 63: 912-916.
17. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, et al. (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269-2271.
18. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, et al. (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306-2310.
19. Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, et al. (2003) Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106: 455-457.
20. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, et al. (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116: 278-290.
21. Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, et al. (2007) An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer research 67: 202-208.
22. Schlondorff J, Lum L, Blobel CP, (2001) Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 276: 14665-14674.
23. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, et al. (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275: 768-775.
24. Ikeda T, Kasai M, Utsuyama M, Hirokawa K, (2001) Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142: 1419-1426.
25. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, et al. (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246: 199-204.
26. Radl J, De Glopper ED, Schuit HR, Zurcher C, (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein- producing clone from old to young C57BL/KaLwRij mice. J Immunol 122: 609-613.
27. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM, (1988) Animal model of human disease. Multiple myeloma. Am J Pathol 132: 593-597.
28. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B, (1999) Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93: 235-241.
29. Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, et al. (2005) The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med 113: 191-205.
30. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, et al. (2002) Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5: 242-251.
31. Garrett IR, Dallas S, Radl J, Mundy GR, (1997) A murine model of human myeloma bone disease. Bone 20: 515-520.
32. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, et al. (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069.
33. Hargreaves PG, Wang F, Antcliff J, Murphy G, Lawry J, et al. (1998) Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol 101: 694-702.
34. Holen I, Drury NL, Hargreaves PG, Croucher PI, (2001) Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol 114: 414-421.
35. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, et al. (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)- converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274: 13613-13618.
36. Dougall WC, Chaisson M, (2006) The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer metastasis reviews 25: 541-549.
37. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, et al. (2006) Denosumab in postmenopausal women with low bone mineral density. The New England journal of medicine 354: 821-831.
38. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine 361: 756-765.
39. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, et al. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical cancer research 12: 1221-1228.
40. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, et al. (2010) Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. Journal of bone and mineral research 25: 440-446.